Sibylle Loibl, MD, PhD, German Breast Group, Neu-Isenburg, Germany, shares her highlights from the San Antonio Breast Cancer Symposium (SABCS) 2022, including in HER2-low breast, and new data in sacituzumab govitecan as well as the Akt inhibitor capivasertib. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.